N6-Acryloyl Ibrutinib
| Product Name | N6-Acryloyl Ibrutinib |
|---|---|
| Alternate Names | Ibrutinib Impurities, Impurities of Ibrutinib |
| CAT No. | CS-T-64851 |
| CAS No. | 2031255-27-1 |
| Category | Impurities |
| Stock | IN-Stock |
| Mol. Wt. | 494.54 g/mol |
| Mol. For. | C₂₈H₂₆N₆O₃ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Ibrutinib |
| Smileys | C=CC(N1C[C@H](N2N=C(C3=CC=C(OC4=CC=CC=C4)C=C3)C5=C(NC(C=C)=O)N=CN=C52)CCC1)=O |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
N6-Acryloyl Ibrutinib is a chemical compound used in the development of inhibitors for Bruton's tyrosine kinase (BTK). BTK is an enzyme that plays a crucial role in the activation of B cells, which are responsible for the production of antibodies. Inhibiting BTK has been shown to be an effective treatment for certain types of cancers, such as B-cell lymphomas and leukemias.
N6-Acryloyl Ibrutinib is synthesized by reacting Ibrutinib, a known BTK inhibitor, with acrylic acid. The resulting compound is a derivative of Ibrutinib with an acryloyl group attached to the N6 position. This modification enhances the potency of the inhibitor and improves its selectivity for BTK over other kinases.
In addition to its use in cancer treatment, N6-Acryloyl Ibrutinib has also been studied for its potential as an anti-inflammatory agent. BTK has been implicated in the regulation of inflammatory responses, and inhibiting its activity may have therapeutic benefits for diseases such as rheumatoid arthritis and asthma.
Overall, N6-Acryloyl Ibrutinib is a promising compound in the development of targeted cancer therapies and may have potential applications in the treatment of inflammatory diseases.
Get an Instant Quote
Related Compounds
ibrutinib acetyl impurity | Ibrutinib Impurity 15 | Rac -Ibrutinib propionaldehyde | Ibrutinib Impurity 7 | Ibrutinib N-Oxide impurity | N-Desacryloyl N-(3-Acryloyl-propanoyl) Ibrutinib | Ibrutinib Michael addition adduct | Ibrutinib Dimer | Ibrutinib Impurity 12 | Ibrutinib Impurity 6 | Ibrutinib Di-piperidine impurity | Ibrutinib impurity Dimer | Ibrutinib Impurity 9 | Ibrutinib Piperidine impurity | Ibrutinib Impurity 1 | N1-(2-Carboxyethyl) Ibrutinib | Ibrutinib Piperidine N-desacryl impurity | Ibrutinib Impurity D | Ibrutinib Impurity 8 | N-Desacryloyl N-3-hydroxypropanoyl Ibrutinib | Ibrutinib Amino Piperidine dihydrochloride Impurity | Ibrutinib Impurity 42 | Ibrutinib (IBR) Diamine Impurity | Ibrutinib Impurity L | Ibrutinib impurity 25 | Ibrutinib Hydroxy Impurity | Ibrutinib N1-Oxide |